14-3-3η Protein, Disease Activity and Bone Mineral Density, in Female Patients With Rheumatoid Arthritis

14-3-3η Protein, Disease Activity and Bone Mineral Density, in Female Patients With Rheumatoid Arthritis

Is to investigate the relation between 14-3-3η protein, disease activity, and bone mineral density in female patients with rheumatoid arthritis.

Methods: all patients in the study will subject to:

• Clinical assessment, WT, Height ,BMI, parity, medications,
• DAS 28.
• Serum 14-3-3η protein.
• DEXA scan.

Grouping:

• Group I: RA Patients with low BMD.
• Group II: RA Patients with normal BMD.
• Group III: normal control.

Inclusion Criteria:

• Rheumatoid arthritis according to ACR 2010 criteria with at least one year duration.
• Premenopausal females.
• On conventional DMARD with maximum 5 mg steroids.

Exclusion Criteria:

• Biological treatment.
• Previous antiresorptive treatment, or bone anabolics.
• High dose corticosteroid.
• Chronic renal or kidney disease.
• Medications affecting bone metabolism.
• Thyroid or adrenal dysfunction,